BACKGROUND

NeoMetrix Dx, Inc. technology grew out of work pioneered by Dr. Charles E. Ahlfors (NeoMetrix Dx founder) at California Pacific Medical Center (CPMC). He has worked closely with a group of preeminent academic thought leaders, including Drs. David Stevenson and Vinod Bhutani at Stanford University and Dr. Richard Wennberg at the University of Washington, to investigate the role of Bf in brain injury and the methods for measuring Bf in jaundiced newborns. Their research has contributed to a large body of scientific publications that show Bf correlates significantly better with poor neurological outcomes in jaundiced newborns and that BT alone poorly correlates with adverse neurological outcomes. (i.e., BT alone does not predict bilirubin brain injury).

NEOMETRIX DX PATENT

NeoMetrix Dx, Inc. has an issued patent (#62652266) titled “Methods and Device for Assessing in Vivo Toxic Levels of Bilirubin and Diagnosing Increased Risk of Bilirubin Neurotoxicity”. The patent protects the automated testing and analysis of BTmax and KA.